Research Analysts Offer Predictions for RARE FY2025 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a research report issued on Monday, July 14th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will earn ($5.15) per share for the year, down from their previous estimate of ($5.08). The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical’s FY2026 earnings at ($3.00) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. The business had revenue of $139.29 million for the quarter, compared to analyst estimates of $145.98 million. During the same period in the prior year, the company posted ($2.03) earnings per share. The company’s revenue was up 28.0% compared to the same quarter last year.

Several other research firms also recently weighed in on RARE. William Blair began coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They issued an “outperform” rating and a $65.00 target price for the company. Morgan Stanley reduced their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a report on Monday. Wedbush reduced their target price on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a report on Monday. JPMorgan Chase & Co. boosted their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. Finally, Wells Fargo & Company reduced their target price on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a report on Thursday, July 10th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $83.64.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $27.31 on Wednesday. Ultragenyx Pharmaceutical has a fifty-two week low of $26.85 and a fifty-two week high of $60.37. The company has a market capitalization of $2.58 billion, a P/E ratio of -4.64 and a beta of 0.26. The stock has a 50-day simple moving average of $36.00 and a 200-day simple moving average of $38.46.

Institutional Trading of Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its stake in shares of Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 323 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Ultragenyx Pharmaceutical by 1,061.9% during the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 669 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $35,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth approximately $57,000. Finally, Headlands Technologies LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth approximately $59,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company’s stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the sale, the director directly owned 15,344 shares of the company’s stock, valued at $573,712.16. This represents a 13.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders sold 3,167 shares of company stock worth $118,824. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.